CN102746336B - 氨基磷酸酯烷化剂前体药物 - Google Patents

氨基磷酸酯烷化剂前体药物 Download PDF

Info

Publication number
CN102746336B
CN102746336B CN201210251557.3A CN201210251557A CN102746336B CN 102746336 B CN102746336 B CN 102746336B CN 201210251557 A CN201210251557 A CN 201210251557A CN 102746336 B CN102746336 B CN 102746336B
Authority
CN
China
Prior art keywords
cancer
alkylating agent
compound
phosphoramidate alkylating
phosphoramidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210251557.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102746336A (zh
Inventor
M·麦特尔西
J-X·段
H·焦
J·凯泽曼
S·阿蒙斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Co ltd
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of CN102746336A publication Critical patent/CN102746336A/zh
Application granted granted Critical
Publication of CN102746336B publication Critical patent/CN102746336B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201210251557.3A 2005-06-29 2006-06-29 氨基磷酸酯烷化剂前体药物 Active CN102746336B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69575505P 2005-06-29 2005-06-29
US60/695,755 2005-06-29
CN2006800300828A CN101501054B (zh) 2005-06-29 2006-06-29 氨基磷酸酯烷化剂前体药物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2006800300828A Division CN101501054B (zh) 2005-06-29 2006-06-29 氨基磷酸酯烷化剂前体药物

Publications (2)

Publication Number Publication Date
CN102746336A CN102746336A (zh) 2012-10-24
CN102746336B true CN102746336B (zh) 2015-08-19

Family

ID=37596083

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210251557.3A Active CN102746336B (zh) 2005-06-29 2006-06-29 氨基磷酸酯烷化剂前体药物
CN2006800300828A Active CN101501054B (zh) 2005-06-29 2006-06-29 氨基磷酸酯烷化剂前体药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2006800300828A Active CN101501054B (zh) 2005-06-29 2006-06-29 氨基磷酸酯烷化剂前体药物

Country Status (23)

Country Link
US (4) US8003625B2 (enExample)
EP (2) EP1896040B1 (enExample)
JP (2) JP5180824B2 (enExample)
KR (1) KR101198571B1 (enExample)
CN (2) CN102746336B (enExample)
AU (2) AU2006263433B8 (enExample)
BR (1) BRPI0612845A8 (enExample)
CA (1) CA2613312C (enExample)
CY (1) CY1113250T1 (enExample)
DK (1) DK1896040T3 (enExample)
ES (2) ES2389532T3 (enExample)
HR (1) HRP20120803T1 (enExample)
IL (1) IL188236A (enExample)
NO (1) NO334420B1 (enExample)
NZ (1) NZ565378A (enExample)
PL (1) PL1896040T3 (enExample)
PT (1) PT1896040E (enExample)
RS (1) RS52505B (enExample)
RU (1) RU2414475C2 (enExample)
SI (1) SI1896040T1 (enExample)
TW (1) TWI384989B (enExample)
WO (1) WO2007002931A2 (enExample)
ZA (1) ZA200800314B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1896040T1 (sl) 2005-06-29 2012-12-31 Threshold Pharmaceuticals, Inc. Fosforamidatna alkilatorska predzdravila
ES2884044T3 (es) * 2006-12-26 2021-12-10 Immunogenesis Inc Profármaco alquilante de fosforamidato para el tratamiento del cáncer
WO2008124691A1 (en) 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
WO2009018163A1 (en) * 2007-07-27 2009-02-05 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of anthracyclines
UA104579C2 (uk) 2007-12-10 2014-02-25 Байокрист Фармасьютикалз, Инк. Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом
CN102256966B (zh) 2008-10-17 2016-02-10 白头生物医学研究所 可溶性mTOR复合物和其调节剂
JP5765634B2 (ja) * 2008-10-21 2015-08-19 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
MX2012014416A (es) * 2010-06-28 2013-02-27 Threshold Pharmaceuticals Inc Tratamiento de cancer de sangre.
KR20130045341A (ko) 2010-07-12 2013-05-03 쓰레솔드 파마슈티컬스, 인코포레이티드 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여
KR20140038390A (ko) * 2011-04-01 2014-03-28 쓰레솔드 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
RU2013147744A (ru) * 2011-04-15 2015-05-20 Тресхолд Фармасьютикалз, Инк. Дозированная лекарственная форма для перорального применения
WO2012145684A1 (en) * 2011-04-22 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Transient hypoxia inducers and their use
CN102850397B (zh) * 2011-06-29 2015-02-18 北京大学 多靶点抗肿瘤化合物及其制备方法和应用
CN102924507A (zh) * 2011-11-10 2013-02-13 安徽四维药业有限公司 一种抗肿瘤化合物及其制备方法与应用、药物组合物
EP2793899A4 (en) * 2011-12-22 2015-06-17 Threshold Pharmaceuticals Inc HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT
JP2015500885A (ja) * 2011-12-22 2015-01-08 スレッショルド ファーマシューティカルズ，インコーポレイテッド 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
EP2817011B1 (en) * 2012-02-21 2022-01-05 ImmunoGenesis, Inc. Treatment of cancer
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
EP2870169A1 (en) * 2012-07-03 2015-05-13 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
DE102012213838A1 (de) * 2012-08-03 2014-02-06 Katharina Pachmann Verfahren zur Kultivierung einer Subpopulation zirkulierender epithelialer Tumorzellen aus einer Körperflüssigkeit
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
JP5922791B2 (ja) 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
CN105792845A (zh) 2013-07-26 2016-07-20 施瑞修德制药公司 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
WO2015025283A2 (en) 2013-08-20 2015-02-26 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Dual action carbonic anhydrase inhibitors
US20160251387A1 (en) * 2013-10-10 2016-09-01 Merck Patent Gmbh Synthesis of 1-alkyl-2-amino-imidazol-5-carboxylic acid ester via calpha-substituted n-alkyl-glycine ester derivatives
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CN104628772A (zh) * 2013-11-07 2015-05-20 四川恒康发展有限责任公司 一种抗肿瘤前药及其激活剂、组合物和应用
EP3623364A1 (en) * 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016011195A1 (en) * 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
SG11201707293VA (en) 2015-03-10 2017-10-30 Ascenta Pharmaceuticals Ltd Dna alkylating agents
US10829437B2 (en) 2015-04-02 2020-11-10 Obi Pharma, Inc. Nitrobenzyl derivatives of anti-cancer agents
CN105037427B (zh) * 2015-06-22 2017-05-31 石家庄学院 丹参酮iia亚乙基亚胺磷酸酯衍生物及其制备方法与应用
PL412787A1 (pl) 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
US20180169064A1 (en) * 2015-06-24 2018-06-21 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
AU2016357728B2 (en) * 2015-11-16 2020-08-27 Obi Pharma, Inc. (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
CN109219610A (zh) * 2016-04-04 2019-01-15 新泽西州立拉特格斯大学 拓扑异构酶毒物
EP4549467A3 (en) 2016-08-01 2025-07-23 ImmunoGenesis, Inc. Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
GEP20217227B (en) 2017-01-06 2021-02-25 Pharmaceuticals Inc Rivus Novel phenyl derivatives
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
WO2019238817A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting rpn11
KR20210020107A (ko) 2018-06-13 2021-02-23 암피스타 테라퓨틱스 엘티디 UchL5 표적화를 위한 이중작용성 분자
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
CN110746459A (zh) * 2018-07-24 2020-02-04 上海喀露蓝科技有限公司 一种艾伏磷酰胺的制备方法
EP3650046A1 (en) 2018-11-08 2020-05-13 Cellis AG Mesenchymal stem cell based targeted active ingredient delivery system
CN109705187B (zh) * 2019-01-29 2021-08-20 石家庄学院 一种雷公藤红素衍生物及其制备方法与应用
CN112755001B (zh) * 2019-11-01 2022-04-12 深圳艾欣达伟医药科技有限公司 口服给药的固体剂型药物
AU2021237774A1 (en) 2020-03-18 2022-09-22 Cellis Ag Ferritin variants with increased stability, complexation ability and transferrin receptor affinity
WO2022195092A1 (en) 2021-03-18 2022-09-22 Cellis Ag Ferritin variants with increased stability and complexation ability
CN117651548A (zh) 2021-08-27 2024-03-05 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
CN118076359A (zh) * 2021-08-27 2024-05-24 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
WO2023226959A1 (zh) 2022-05-23 2023-11-30 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN115840004B (zh) * 2022-08-08 2024-12-13 中国医学科学院基础医学研究所 一种检测视黄醇代谢产物的试剂在制备诊断和/或治疗尘肺病工具中的应用
WO2024056413A1 (en) 2022-09-13 2024-03-21 Cellis Ag Isolated targeted delivery system for the treatment of glioma
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
WO2024112663A1 (en) 2022-11-21 2024-05-30 Rivus Pharmaceuticals, Inc. Deuterium enriched phenyl derivatives for treating mitochondriarelated disorders or conditions
EP4637829A1 (en) 2022-12-20 2025-10-29 Cellis Sp. z o.o. ([Ltd.] Isolated targeted delivery system for the treatment of ovarian cancer
WO2024179467A1 (zh) * 2023-02-27 2024-09-06 深圳艾欣达伟医药科技有限公司 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法
WO2025083276A1 (en) 2023-10-19 2025-04-24 Cellis Ag Improved isolated targeted delivery system
CN117756848A (zh) * 2023-11-30 2024-03-26 常州大学 一种th-302衍生物及其制备方法
CN117777196A (zh) * 2023-12-01 2024-03-29 常州大学 艾伏磷酰胺异构体衍生物的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008850A1 (en) * 1999-07-14 2003-01-09 Borch Richard F. Phosphoramide compounds

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652579A (en) 1969-06-26 1972-03-28 Hoffmann La Roche 1-methyl-2-substituted 5-nitroimidazoles
DE2229248C3 (de) 1971-07-30 1980-03-27 Gruppo Lepetit S.P.A., Mailand (Italien) 5-Iminomethyl-2-nitroimidazoI-Derivate und Verfahren zu deren Herstellung
US4921963A (en) 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
JPH0819111B2 (ja) 1987-10-22 1996-02-28 ポーラ化成工業株式会社 ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
US5403932A (en) 1988-05-25 1995-04-04 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US5190929A (en) 1988-05-25 1993-03-02 Research Corporation Technologies, Inc. Cyclophosphamide analogs useful as anti-tumor agents
US4908356A (en) 1988-05-25 1990-03-13 Research Corporation Technologies, Inc. Aldophosphamide derivatives useful as antitumor agents
DE3835772A1 (de) * 1988-10-20 1990-04-26 Deutsches Krebsforsch Tumorhemmende saccharid-konjugate
KR927003539A (ko) 1990-01-26 1992-12-18 스즈끼 쯔네시 2-니트로 이미다졸 유도체, 그의 제조방법 및 이를 유효성분으로 하는 방사선 증감제
HU9201539D0 (en) 1990-09-11 1992-08-28 Kortec Ag Method and device for gasifying gasifiable materials and/or transforming gas as well as heat exchanger of high temperature for executing said method
US5233031A (en) 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
EP0638123B1 (en) 1991-10-23 2006-12-27 Cancer Research Technology Limited Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form
US5750782A (en) 1992-11-27 1998-05-12 Cancer Research Campaign Technology Limited Nitroaniline derivatives and their use as anti-tumour agents
US5306727A (en) * 1993-04-30 1994-04-26 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US5691371A (en) 1993-05-25 1997-11-25 Auckland Uniservices Limited Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents
DE69425356T2 (de) 1993-09-22 2002-04-18 Hoechst Ag Pro-Prodrugs, ihre Herstellung und Anwendung
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5659061A (en) * 1995-04-20 1997-08-19 Drug Innovation & Design, Inc. Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
GB9516943D0 (en) 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
SI0795334T1 (sl) * 1996-03-12 2006-06-30 Sanofi Aventis Deutschland Predzdravila za zdravljenje tumorjev in vnetnih bolezni
US6218519B1 (en) 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
US5728271A (en) 1996-05-20 1998-03-17 Rti Resource Transforms International Ltd. Energy efficient liquefaction of biomaterials by thermolysis
ES2155249T3 (es) 1996-05-20 2001-05-01 Dynamotive Technologies Corp Licuefaccion con alto rendimiento energetico de biomateriales por termolisis.
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6251933B1 (en) 1996-12-13 2001-06-26 The Cancer Research Campaign Technology Limited Seco precursors of cyclopropylindolines and their use as prodrugs
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US7914994B2 (en) 1998-12-24 2011-03-29 Cepheid Method for separating an analyte from a sample
US6240925B1 (en) 1999-03-23 2001-06-05 Cynosure, Inc. Photothermal vascular targeting with bioreductive agents
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
DE60007120T2 (de) 1999-05-24 2004-09-16 Southern Research Institute, Birmingham Isophosphoramide-senfgasanalogen und deren verwendung
AU5331300A (en) 1999-06-11 2001-01-02 Henceforth Hibernia, Inc. Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions
WO2001074827A1 (en) 2000-03-31 2001-10-11 Purdue Research Foundation Phosphoramidate prodrugs
US20030091574A1 (en) 2001-03-23 2003-05-15 Gevas Philip C. Combination treatment of pancreatic cancer
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6506739B1 (en) 2001-05-01 2003-01-14 Telik, Inc. Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents
WO2002096910A1 (en) 2001-05-31 2002-12-05 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
FR2825926A1 (fr) 2001-06-14 2002-12-20 Sod Conseils Rech Applic Derives d'imidazoles modulant les canaux sodiques
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
KR20030067275A (ko) 2002-02-07 2003-08-14 주식회사 하이폭시 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제
US20040009667A1 (en) 2002-02-07 2004-01-15 Etsuo Iijima Etching method
HUE026218T2 (en) 2002-02-21 2016-05-30 Inst Virology MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
JP4227771B2 (ja) 2002-07-17 2009-02-18 三菱重工業株式会社 バイオマスのガス化方法
US6833390B2 (en) 2002-07-22 2004-12-21 Bayer Polymers Llc Process for preparing closed-cell water-blown rigid polyurethane foams having improved mechanical properties
DE10237931A1 (de) 2002-08-14 2004-02-26 Endress + Hauser Gmbh + Co. Kg Vorrichtung zur Überwachung eines vorbestimmten Füllstands eines Messmediums in einem Behälter
ES2309484T3 (es) 2003-01-09 2008-12-16 Pfizer Inc. Derivados de diazepinoindol como inhibidores de quinasa.
GB0306908D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Bioreductively activated stilbene prodrugs
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
US6855695B2 (en) 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
US7340059B2 (en) 2003-06-17 2008-03-04 Intel Corporation Programmable scrambler and De-scrambler for digital telephony equipment
JP2005041733A (ja) 2003-07-28 2005-02-17 National Institute Of Advanced Industrial & Technology バイオマスによる水素製造法
NZ549605A (en) 2004-02-06 2010-01-29 Threshold Pharmaceuticals Inc Use of glufosfamide to treat chemotherapy-refractory pancreatic cancer
US7432106B2 (en) 2004-03-24 2008-10-07 Applied Biosystems Inc. Liquid processing device including gas trap, and system and method
EP1743038A4 (en) 2004-05-04 2007-11-21 Bayer Healthcare MN / CA IX / CA9 AND KIDNEY CANCER PROGNOSIS
IL162713A (en) 2004-06-24 2011-04-28 Desalitech Ltd Apparatus and methods for continuous desalination in closed circuit without containers
TW200605885A (en) 2004-07-29 2006-02-16 Threshold Pharmaceuticals Inc Multicyclic lonidamine analogs
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
US20090042820A1 (en) 2004-11-22 2009-02-12 Threshold Pharmaceuticals, Inc. Tubulin Binding Anti Cancer Agents And Prodrugs Thereof
US20070117784A1 (en) 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
SI1896040T1 (sl) 2005-06-29 2012-12-31 Threshold Pharmaceuticals, Inc. Fosforamidatna alkilatorska predzdravila
CA2624707A1 (en) 2005-10-03 2007-04-12 Genetix Pharmaceuticals, Inc. Method for selectively depleting hypoxic cells
WO2008011588A2 (en) 2006-07-20 2008-01-24 Threshold Pharmaceuticals, Inc. Glycoconjugates of phosphoramidate alkylators for treatment of cancer
WO2008033041A1 (en) 2006-09-11 2008-03-20 Auckland Uniservices Limited Cancer treatment
JP2008069017A (ja) 2006-09-12 2008-03-27 Matsushita Electric Ind Co Ltd 水素製造方法
US7807454B2 (en) 2006-10-18 2010-10-05 The Regents Of The University Of California Microfluidic magnetophoretic device and methods for using the same
WO2008076826A1 (en) 2006-12-13 2008-06-26 Threshold Pharmaceuticals, Inc. Pyrophosphoramide alkylators
ES2884044T3 (es) 2006-12-26 2021-12-10 Immunogenesis Inc Profármaco alquilante de fosforamidato para el tratamiento del cáncer
JP5174411B2 (ja) 2007-09-28 2013-04-03 独立行政法人石油天然ガス・金属鉱物資源機構 管式リフォーマーの有効熱利用方法
US8216607B2 (en) 2008-03-17 2012-07-10 Roger Williams Hospital Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer
JP5731372B2 (ja) 2008-04-10 2015-06-10 ヴァージニア コモンウェルス ユニバーシティ 癌治療用腫瘍低酸素の誘発
US8501765B2 (en) 2008-06-11 2013-08-06 Genentech, Inc. Diazacarbazoles and methods of use
JP4665021B2 (ja) 2008-09-03 2011-04-06 三菱重工業株式会社 バイオマスのガス化方法
JP5765634B2 (ja) 2008-10-21 2015-08-19 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
WO2010108091A2 (en) 2009-03-20 2010-09-23 Pbs Biotech, Inc. Automatable aseptic sample withdrawal system
CA2760932A1 (en) 2009-05-04 2010-11-11 Thierry Nivaggioli Mtor pathway inhibitors for treating ocular disorders
MX2012005163A (es) 2009-11-06 2012-11-22 Infinity Pharmaceuticals Inc Formulaciones orales de un inhibidor de la ruta de hedgehog.
JP5659536B2 (ja) 2010-03-31 2015-01-28 新日鐵住金株式会社 タール含有ガスの改質用触媒及びその製造方法、並びにタール含有ガスの改質方法
MX2012014416A (es) 2010-06-28 2013-02-27 Threshold Pharmaceuticals Inc Tratamiento de cancer de sangre.
KR20130045341A (ko) 2010-07-12 2013-05-03 쓰레솔드 파마슈티컬스, 인코포레이티드 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여
US10357577B2 (en) 2010-07-16 2019-07-23 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
KR20140038390A (ko) 2011-04-01 2014-03-28 쓰레솔드 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
RU2013147744A (ru) 2011-04-15 2015-05-20 Тресхолд Фармасьютикалз, Инк. Дозированная лекарственная форма для перорального применения
JP5805989B2 (ja) 2011-04-26 2015-11-10 大塚電子株式会社 電気泳動移動度測定用セル並びにそれを用いた測定装置及び測定方法
MY178682A (en) 2011-12-20 2020-10-20 Biomass Energy Corp Method and device for producing synthetic gas and method and device for synthesizing liquid fuel
EP2793899A4 (en) 2011-12-22 2015-06-17 Threshold Pharmaceuticals Inc HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT
JP2015511226A (ja) 2012-01-31 2015-04-16 スレッショルド ファーマシューティカルズ，インコーポレイテッド 低酸素活性化プロドラッグ療法のための予測バイオマーカー

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008850A1 (en) * 1999-07-14 2003-01-09 Borch Richard F. Phosphoramide compounds

Also Published As

Publication number Publication date
WO2007002931A2 (en) 2007-01-04
DK1896040T3 (da) 2012-09-03
JP2012153722A (ja) 2012-08-16
ZA200800314B (en) 2009-09-30
KR101198571B1 (ko) 2012-11-07
EP1896040A4 (en) 2010-02-10
AU2011202075B2 (en) 2013-01-17
AU2006263433A1 (en) 2007-01-04
NO20080442L (no) 2008-03-31
IL188236A (en) 2011-11-30
IL188236A0 (en) 2008-08-07
NZ565378A (en) 2011-03-31
KR20080027901A (ko) 2008-03-28
US20130303778A1 (en) 2013-11-14
AU2011202075A8 (en) 2013-05-30
US8664204B2 (en) 2014-03-04
TWI384989B (zh) 2013-02-11
US20100137254A1 (en) 2010-06-03
EP2336141A2 (en) 2011-06-22
BRPI0612845A2 (pt) 2010-11-30
CN101501054A (zh) 2009-08-05
HRP20120803T1 (hr) 2012-11-30
JP5781007B2 (ja) 2015-09-16
AU2011202075A1 (en) 2011-05-26
NO334420B1 (no) 2014-03-03
BRPI0612845A8 (pt) 2018-01-23
US20140170240A1 (en) 2014-06-19
AU2006263433B8 (en) 2011-06-09
EP1896040B1 (en) 2012-08-01
JP5180824B2 (ja) 2013-04-10
CN102746336A (zh) 2012-10-24
PL1896040T3 (pl) 2012-12-31
US8003625B2 (en) 2011-08-23
US8507464B2 (en) 2013-08-13
WO2007002931A3 (en) 2009-04-23
CN101501054B (zh) 2012-09-05
TW200800228A (en) 2008-01-01
CA2613312C (en) 2014-10-14
PT1896040E (pt) 2012-09-27
ES2579235T3 (es) 2016-08-08
CA2613312A1 (en) 2007-01-04
AU2011202075B8 (en) 2013-05-30
ES2389532T3 (es) 2012-10-29
RU2414475C2 (ru) 2011-03-20
US20110251159A1 (en) 2011-10-13
EP2336141A3 (en) 2011-09-14
JP2009502743A (ja) 2009-01-29
RS52505B (sr) 2013-04-30
EP2336141B1 (en) 2016-03-30
RU2008103195A (ru) 2009-08-10
CY1113250T1 (el) 2016-04-13
US9226932B2 (en) 2016-01-05
AU2006263433B2 (en) 2011-06-02
HK1113754A1 (en) 2008-10-17
EP1896040A2 (en) 2008-03-12
SI1896040T1 (sl) 2012-12-31

Similar Documents

Publication Publication Date Title
CN102746336B (zh) 氨基磷酸酯烷化剂前体药物
JP5572644B2 (ja) 癌を処置するための組成物および方法
US20090042820A1 (en) Tubulin Binding Anti Cancer Agents And Prodrugs Thereof
US20080214576A1 (en) Topoisomerase Inhibitors and Prodrugs
CN101094838A (zh) 微管蛋白结合抗癌药及其前体药物
WO2007137196A2 (en) Tubulin binding anti cancer compounds and prodrugs thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Texas, USA

Patentee after: Molecular Template Co.,Ltd.

Address before: California, USA

Patentee before: Threshold Pharmaceuticals, Inc.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231114

Address after: Texas, USA

Patentee after: Immune Response Co.,Ltd.

Address before: Texas, USA

Patentee before: Molecular Template Co.,Ltd.